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Background
Antibodies directed against antigen-presenting cell (APC)
receptors can deliver antigens very efficiently. This recep-
tor-targeting vaccine system facilitates the uptake, process-
ing and presentation of extracellular antigens. In our
approach, an antibody against human CD40 was fused to
HIV antigens and these prototype vaccines were tested for
their capacity to stimulate the expansion of HIV-specific
memory T cells.
Methods
Recombinant anti-CD40 antibodies fused to HIV Gag
and/or Nef proteins were tested for their capacity to bind
to DCs and to stimulate expansion of HIV-specific T cells.
PBMC and dendritic cells (DC) from HIV-infected
patients were incubated with Gag-targeting molecules fol-
lowed by anti-Gag PE secondary antibody. Binding on in
CD19+, CD14+ and CD11c+ cells was measured by flow
cytometry. Short-term PBMC cultures (10 days) stimu-
lated with DC-targeting vaccines in the presence of IL-2
were re-stimulated with overlapping peptides covering the
total sequences of Gag and Nef, followed by multiplex
cytokine (Luminex) analysis of supernatants and intracel-
lular staining.
Results
The anti-CD40-HIV-Gag/Nef antibodies bind to B cells,
monocytes and DC with a affinity similar to the parental
anti-CD40 antibody. The HIV antigen-targeting vaccines
displayed a high stimulation capacity in vitro compared
with isotype control (IgG4) fusion proteins, inducing
CD4+ and CD8+ T cell responses against Gag and Nef
peptides even at very low concentrations (0.01 nM).
Moreover, we observed not only antigen-specific secretion
of the Th1/CTL set of cytokines but also of cytokines char-
acteristic of Th2 and IL-21 subsets. The breadth and the
quality of the T cell responses observed in PBMC cultures
matched responses those observed in DC-T cell co-cul-
tures.
Conclusion
Thus CD40 is an excellent candidate for HIV vaccines
based on DC targeting, as it's activation not only causes
maturation of APC but permits efficient presentation and
cross-presentation of HIV epitopes, thereby stimulating
strong recall T cell responses.
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